1352733-99-3

Usage

Uses

Used in Pharmaceutical Industry:
TFBM is used as a key intermediate in the synthesis of pharmaceutical compounds for [application reason]. Its unique structure allows for the development of new drugs with improved properties, such as enhanced potency, selectivity, and reduced side effects.
Used in Agrochemical Industry:
TFBM is used as a building block in the creation of agrochemicals for [application reason]. Its incorporation into agrochemical formulations can lead to the development of more effective and environmentally friendly pesticides, herbicides, and other agricultural products.
Used in Materials Science:
TFBM is used as a component in the development of advanced materials for [application reason]. Its unique properties can contribute to the creation of materials with improved performance characteristics, such as enhanced mechanical strength, thermal stability, or electrical conductivity.
Used in Organic Chemistry Research:
TFBM is used as a reagent and building block in organic chemistry research for [application reason]. Its versatility and unique structure make it an invaluable tool for chemists exploring new reaction pathways, developing novel synthetic methods, and discovering new compounds with potential applications in various fields.

Upstream product

• 99725-13-0 (5-bromo-2-fluorophenyl)methanol 
• 73183-34-3 bis(pinacol)diborane 
• 374538-01-9 (4-fluoro-3-formylphenyl)boronic acid 
• 443776-94-1 2-fluoro-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzaldehyde 
• 446-51-5 2-fluorobenzyl alcohol 

Downstream Products

• 1544739-49-2 (5aR,6S,6aS)-ethyl 3-((4-fluoro-4’-((S)-2-hydroxypropoxy)-2’,6’-dimethyl-[1,1’-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-47-0 (5aR,6S,6aS)-3-((4-fluoro-4’-((S)-2-hydroxypropoxy)-2’,6’-dimethyl-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544739-59-4 (5aR,6S,6aS)-ethyl 3-((4-fluoro-4’-(2-(1-hydroxycyclopropyl)ethoxy)-2’-(trifluoromethyl)-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]-cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-56-1 (5aR,6S,6aS)-3-((4-fluoro-4’-(2-(1-hydroxycyclopropyl)ethoxy)-2’-(trifluoromethyl)-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544739-68-5 ethyl 3-((4-fluoro-4’-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-2’,6’-dimethyl-[1,1’-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-61-8 (5aR,6S,6aS)-3-((4-fluoro-4’-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-2’,6’-dimethyl-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544739-74-3 (5aR,6S,6aS)-ethyl 3-((2’,4-difluoro-4’-(3-(methylsulfonyl)propoxy)-6’-(trifluoromethyl)-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]-cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-71-0 (5aR,6S,6aS)-3-((2’,4-difluoro-4’-(3-(methylsulfonyl)propoxy)-6’-(trifluoromethyl)-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544740-48-8 (5aR,6S,6aS)-ethyl 3-((2-fluoro-5-(6-((4-hydroxy-4-methylpentyl)oxy)-4-(trifluoromethyl)pyridin-3-yl) benzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544740-44-4 (5aR,6S,6aS)-3-((2-fluoro-5-(6-((4-hydroxy-4-methylpentyl)oxy)-4-(trifluoromethyl)pyridin-3-yl) benzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544741-33-4 (5aR,6S,6aS)-ethyl 3-((4-fluoro-2’,6’-dimethyl-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544740-50-2 (5aR,6S,6aS)-3-((4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544740-80-8 4-[2-fluoro-5-(2-trifluoromethyl-phenoxy)-benzyloxy]-1,1a,6,6a-tetrahydro-3-aza-cyclopropa[a]indene-1-carboxylic acid ethyl ester 
• 1544740-79-5 4-[2-fluoro-5-(2-trifluoromethyl-phenoxy)-benzyloxy]-1,1a,6,6a-tetrahydro-3-aza-cyclopropa[a]indene-1-carboxylic acid 

Relevant academic research and scientific papers

Para-Selective, Iridium-Catalyzed C-H Borylations of Sulfated Phenols, Benzyl Alcohols, and Anilines Directed by Ion-Pair Electrostatic Interactions

Para C-H borylations (CHB) of tetraalkylammonium sulfates and sulfamates have been achieved using bipyridine-ligated Ir boryl catalysts. Selectivities can be modulated by both the length of the alkyl groups in the tetraalkylammonium cations and the substituents on the bipyridine ligands. Ion pairing, where the alkyl groups of the cation shield the meta C-H bonds in the counteranions, is proposed to account for para selectivity. The 4,4′-dimethoxy-2,2′-bipyridine ligand gave superior selectivities.

HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS

The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

NRF2 REGULATORS

The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Synthesis of boron-containing primary amines

In this study, boron-containing primary amines were synthesized for use as building blocks in the study of peptoids. In the first step, Gabriel synthesis conditions were modified to enable the construction of seven different aminomethylphenyl boronate esters in good to excellent yields. These compounds were further utilized to build peptoid analogs via an Ugi four-component reaction (Ugi-4CR) under microwave irradiation. The prepared Ugi-4CR boronate esters were then successfully converted to the corresponding boronic acids. Finally, the peptoid structures were successfully modified by cross-coupling to aryl/heteroaryl chlorides via a palladium-mediated Suzuki coupling reaction to yield the corresponding derivatives in moderate to good yields.